Literature DB >> 25450887

Characterization of cellular immune response and innate immune signaling in human and nonhuman primate primary mononuclear cells exposed to Burkholderia mallei.

Shahabuddin Alam1, Kei Amemiya2, Robert C Bernhards2, Robert G Ulrich1, David M Waag2, Kamal U Saikh3.   

Abstract

Burkholderia pseudomallei infection causes melioidosis and is often characterized by severe sepsis. Although rare in humans, Burkholderia mallei has caused infections in laboratory workers, and the early innate cellular response to B. mallei in human and nonhuman primates has not been characterized. In this study, we examined the primary cellular immune response to B. mallei in PBMC cultures of non-human primates (NHPs), Chlorocebus aethiops (African Green Monkeys), Macaca fascicularis (Cynomolgus macaque), and Macaca mulatta (Rhesus macaque) and humans. Our results demonstrated that B. mallei elicited strong primary pro-inflammatory cytokines (IFN-γ, TNF-α, IL-1β, and IL-6) equivalent to the levels of B. pseudomallei in primary PBMC cultures of NHPs and humans. When we examined IL-1β and other cytokine responses by comparison to Escherichia coli LPS, African Green Monkeys appears to be most responsive to B. mallei than Cynomolgus or Rhesus. Characterization of the immune signaling mechanism for cellular response was conducted by using a ligand induced cell-based reporter assay, and our results demonstrated that MyD88 mediated signaling contributed to the B. mallei and B. pseudomallei induced pro-inflammatory responses. Notably, the induced reporter activity with B. mallei, B. pseudomallei, or purified LPS from these pathogens was inhibited and cytokine production was attenuated by a MyD88 inhibitor. Together, these results show that in the scenario of severe hyper-inflammatory responses to B. mallei infection, MyD88 targeted therapeutic intervention may be a successful strategy for therapy. Published by Elsevier Ltd.

Entities:  

Keywords:  Burkholderia mallei; Burkholderia pseudomallei; Cytokines; Glanders; Immune-pathogenesis; Inflammation; Melioidosis; MyD88

Mesh:

Substances:

Year:  2014        PMID: 25450887     DOI: 10.1016/j.micpath.2014.11.009

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  6 in total

Review 1.  Innate immune response to Burkholderia mallei.

Authors:  Kamal U Saikh; Tiffany M Mott
Journal:  Curr Opin Infect Dis       Date:  2017-06       Impact factor: 4.915

2.  An increase in intracellular p62/NBR1 and persistence of Burkholderia mallei and B. pseudomallei in infected mice linked to autophagy deficiency.

Authors:  Kamal U Saikh; Jennifer L Dankmeyer; Xiankun Zeng; Robert G Ulrich; Kei Amemiya
Journal:  Immun Inflamm Dis       Date:  2018-12-19

3.  A reverse-phase protein microarray-based screen identifies host signaling dynamics upon Burkholderia spp. infection.

Authors:  Chih-Yuan Chiang; Ijeoma Uzoma; Douglas J Lane; Vesna Memišević; Farhang Alem; Kuan Yao; Krishna P Kota; Sina Bavari; Anders Wallqvist; Ramin M Hakami; Rekha G Panchal
Journal:  Front Microbiol       Date:  2015-07-27       Impact factor: 5.640

4.  Characterization of the murine macrophage response to infection with virulent and avirulent Burkholderia species.

Authors:  Chih-Yuan Chiang; Ricky L Ulrich; Melanie P Ulrich; Brett Eaton; Jenifer F Ojeda; Douglas J Lane; Krishna P Kota; Tara A Kenny; Jason T Ladner; Samuel P Dickson; Kathleen Kuehl; Rahul Raychaudhuri; Mei Sun; Sina Bavari; Mark J Wolcott; David Covell; Rekha G Panchal
Journal:  BMC Microbiol       Date:  2015-11-06       Impact factor: 3.605

5.  Bacterial overgrowth and diversification of microbiota in gastric cancer.

Authors:  Lili Wang; Jianhua Zhou; Yongning Xin; Changxin Geng; Zibin Tian; Xinjuan Yu; Quanjiang Dong
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-03       Impact factor: 2.566

6.  The Innate Immune Response in the Marmoset during the Acute Pneumonic Disease Caused by Burkholderia pseudomallei.

Authors:  Sarah Ngugi; Thomas Laws; Andrew J Simpson; Michelle Nelson
Journal:  Infect Immun       Date:  2022-01-18       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.